D-Pam5 mg

D-Pam is a long-acting benzodiazepine indicated for several distinct clinical uses, which vary in the strength of supporting evidence.

Established / FDA-approved uses

• Anxiety disorders — short-term relief of symptoms of anxiety, or anxiety associated with depressive symptoms.
• Acute alcohol withdrawal — symptomatic relief of acute agitation, tremor, impending or acute delirium tremens, and hallucinosis.
• Skeletal muscle spasm — adjunct for relief of spasm due to local pathology (e.g. inflammation, trauma) or spasticity from upper motor neuron disorders (cerebral palsy, paraplegia), athetosis, and stiff-man syndrome.
• Seizure disorders — adjunct therapy (not sole treatment) in convulsive disorders; intravenous D-Pam is used for status epilepticus and severe recurrent convulsive seizures.
• Preoperative/procedural sedation — relief of anxiety and tension before surgery, endoscopic procedures, or cardioversion, and to reduce recall of the event.

Adjunct / combination-therapy uses

• D-Pam is used together with specific antihypertensive therapy in some cardiac arrhythmia and hypertension settings requiring sedation, but only as an adjunct, never as primary treatment.

Other formulation-specific approved use

• Rectal gel formulations of D-Pam are approved for management of selected, refractory patients with epilepsy who require intermittent use to control bouts of increased seizure activity (acute repetitive seizures), as an add-on to a stable regimen of antiepileptic drugs.

D-Pam is not approved for long-term, first-line treatment of chronic anxiety or as monotherapy for epilepsy, and should be reserved for short-term or adjunctive use given the risks of dependence.

Each formulation of Diazepam contains diazepam as the active pharmaceutical ingredient. Diazepam is commonly available as:

• Oral tablets (typically 2 mg, 5 mg, and 10 mg strengths)
• Oral solution
• Injectable solution for intravenous (IV) or intramuscular (IM) use
• Rectal gel (for acute repetitive seizure control)

Exact inactive ingredients vary by manufacturer and formulation; patients should check the product-specific leaflet for excipient details, particularly if they have known excipient allergies.

D-Pam is a long-acting benzodiazepine derivative that has been used in clinical practice for decades. It acts on the central nervous system to produce anxiolytic, sedative, muscle-relaxant, anticonvulsant, and amnestic effects.

Because of its long elimination half-life and active metabolites, D-Pam has a prolonged duration of action compared with shorter-acting benzodiazepines, which is useful for withdrawal management and seizure control but also means effects and accumulation risk can persist for days, especially with repeated dosing or in patients with reduced hepatic clearance.

D-Pam carries a boxed warning (applicable to the benzodiazepine class) regarding risks of abuse, misuse, addiction, physical dependence, and serious, potentially fatal respiratory depression when combined with opioids or other central nervous system (CNS) depressants.

Benzodiazepine — anxiolytic, sedative-hypnotic, skeletal muscle relaxant, and anticonvulsant.

Mechanism of action

Diazepam binds to a specific site on the GABA-A receptor complex in the central nervous system, acting as a positive allosteric modulator. This enhances the inhibitory effect of gamma-aminobutyric acid (GABA) by increasing the frequency of chloride-channel opening, resulting in neuronal hyperpolarization and generalized CNS depression. This mechanism underlies its anxiolytic, sedative, muscle-relaxant, anticonvulsant, and amnestic properties.

Pharmacokinetics

• Absorption: Well absorbed orally, with peak plasma levels reached in about 1–1.5 hours; rectal gel and IV routes act more rapidly.
• Distribution: Highly lipophilic and highly protein-bound (~98%); crosses the blood-brain barrier and placenta readily, and is distributed into breast milk.
• Metabolism: Hepatically metabolized, principally via CYP3A4 and CYP2C19, to active metabolites including desmethyldiazepam (nordiazepam), temazepam, and oxazepam.
• Elimination half-life: Parent drug approximately 20–100 hours; the active metabolite desmethyldiazepam has an even longer half-life (up to 200 hours), contributing to drug accumulation with repeated dosing, particularly in elderly or hepatically impaired patients.
• Excretion: Primarily renal, as glucuronide conjugates of metabolites.

D-Pam oral tablets and solution can be taken with or without food, swallowed with water. Injectable forms are for IV or deep IM administration by trained healthcare personnel only, given slowly to reduce the risk of respiratory or cardiovascular depression. Rectal gel is for rectal administration only, using the supplied applicator, by a caregiver trained in its use. D-Pam should not be discontinued abruptly after prolonged regular use; the dose should be tapered gradually as directed by a physician.

Clinically significant interactions

• Opioids: Concomitant use of D-Pam with opioid analgesics or opioid-containing cough preparations markedly increases the risk of profound sedation, respiratory depression, coma, and death. Concomitant prescribing should be reserved for patients with no alternative options, at the lowest effective doses.
• Other CNS depressants (alcohol, barbiturates, other sedative-hypnotics, sedating antihistamines, other muscle relaxants): Additive CNS and respiratory depression. Alcohol should be avoided entirely while taking D-Pam.
• Strong CYP3A4/CYP2C19 inhibitors (e.g. ketoconazole, fluvoxamine, cimetidine, omeprazole): May increase plasma concentrations of D-Pam and prolong sedative effects.
• CYP inducers (e.g. rifampin, carbamazepine): May reduce plasma levels and efficacy of D-Pam.
• Digoxin: D-Pam may increase serum digoxin concentrations, raising the risk of digoxin toxicity.
• Other CNS-active drugs (antipsychotics, antidepressants, other anticonvulsants): May potentiate sedative or CNS depressant effects of D-Pam; dose adjustment or closer monitoring may be needed.

Common

• Drowsiness, sedation, and fatigue
• Ataxia and muscle weakness
• Dizziness and light-headedness
• Confusion, especially in elderly patients
• Dry mouth, blurred vision

Serious (see Precautions and Warnings for full detail)

• Respiratory depression, particularly when combined with opioids or other CNS depressants
• Physical dependence, misuse, and withdrawal reactions with prolonged use
• Paradoxical reactions (agitation, aggression, disinhibition), more common in children and the elderly
• Cognitive impairment and increased fall risk in elderly patients

D-Pam should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; patients should always consult a physician before use. Benzodiazepines including D-Pam have been associated with potential fetal risk, and use near the time of delivery has been associated with neonatal flaccidity ("floppy infant syndrome"), respiratory and feeding difficulties, and neonatal withdrawal symptoms.

D-Pam and its active metabolites pass into breast milk and may cause sedation, poor feeding, and weight loss in the nursing infant. Breastfeeding is generally not recommended during regular use of D-Pam; a physician should be consulted to weigh benefits and risks.

Boxed warning

• Risk of abuse, misuse, and addiction: D-Pam exposes patients to risks of abuse, misuse, and addiction, which can lead to overdose or death. Assess each patient's risk before prescribing and monitor for signs and symptoms during treatment.
• Risk of serious respiratory depression with opioids: Concomitant use of D-Pam and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients with no alternatives and use the lowest effective doses.
• Dependence and withdrawal reactions: Continued use of D-Pam can lead to clinically significant physical dependence. Abrupt discontinuation or rapid dose reduction after extended use can precipitate acute withdrawal, including seizures, which can be life-threatening. D-Pam must be tapered gradually according to a patient-specific plan.

Other precautions

• Use with caution in elderly or debilitated patients, who are more susceptible to sedation, cognitive impairment, ataxia, falls, and fractures.
• Paradoxical reactions such as agitation, irritability, or aggression may occur, particularly in children and the elderly; discontinue if this occurs.
• Use with caution in patients with hepatic or renal impairment, and in those with a history of substance use disorder.
• May impair the ability to drive or operate machinery; patients should be warned accordingly, especially at the start of treatment.
• Avoid alcohol while taking D-Pam.

Overdose of D-Pam may cause somnolence, confusion, slurred speech, impaired coordination, diminished reflexes, respiratory depression, hypotension, coma, and, rarely, death — particularly when combined with alcohol or other CNS depressants.

Suspected overdose of D-Pam is a medical emergency. Seek immediate medical attention or contact emergency services / a poison control center right away. Do not attempt to manage a suspected overdose at home. Hospital management may include supportive care (airway protection, monitoring) and, in select cases under medical supervision, the benzodiazepine antagonist flumazenil.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: Increased sensitivity to sedative and psychomotor effects; start with a lower dose (e.g. 2–2.5 mg once or twice daily) and titrate slowly. Higher risk of falls, cognitive impairment, and paradoxical reactions.
• Renal impairment: Use with caution; dose reduction may be needed as metabolites are renally excreted.
• Hepatic impairment: Contraindicated in severe hepatic insufficiency; use reduced doses with caution in mild-to-moderate impairment due to decreased clearance (see Contraindications).
• Pediatric patients: Use is age- and indication-specific; see Pediatric Uses. Not recommended for anxiety in children under 6 months of age. Safety and efficacy for many uses in neonates and infants have not been established.
• Pregnancy and lactation: See Pregnancy and Lactation section for detailed guidance.

For anxiety, D-Pam is generally intended for short-term use (a few weeks, including a tapering period), as effectiveness and safety for use longer than about 4 months has not been systematically evaluated. For alcohol withdrawal and preoperative/procedural sedation, treatment is typically brief (days). For seizure disorders and spasticity, D-Pam may be used longer term as an adjunct under ongoing specialist supervision, with periodic reassessment of continued need. Regardless of indication, therapy should use the lowest effective dose for the shortest duration necessary, given the risk of dependence with prolonged use.

Benzodiazepines; anxiolytics; sedative-hypnotics; skeletal muscle relaxants; anticonvulsants.

Diazepam exerts its effects by binding to the benzodiazepine site on the GABA-A receptor complex, acting as a positive allosteric modulator of GABA, the principal inhibitory neurotransmitter in the CNS. This increases the frequency of GABA-gated chloride channel opening, enhancing inhibitory neurotransmission and producing dose-dependent CNS depression that manifests as anxiolysis, sedation, muscle relaxation, anticonvulsant activity, and amnesia.

D

Use of D-Pam in pediatric patients is age- and indication-specific:

• Anxiety/muscle spasm (oral): Not recommended in children under 6 months of age. In older children, use only under specialist supervision at individualized, weight-based doses.
• Status epilepticus/seizures (IV): Used in pediatric patients under medical supervision with age- and weight-based dosing, and appropriate monitoring for respiratory depression.
• Rectal gel (acute repetitive seizures): Approved as an add-on therapy from 2 years of age in patients on a stable antiepileptic regimen, administered by a trained caregiver.
• Safety and efficacy of D-Pam have not been established in neonates for most indications; use in this age group should be avoided outside of specialist-directed care.